India Pharma Outlook Team | Wednesday, 02 July 2025
Jiangsu Recbio Technology Company Limited (02179.HK) signed a licensing cooperation agreement with Biological E. Limited (BE), the Indian vaccine and pharmaceuticals industry leader, in a historic development in the battle against cancer caused by human papillomavirus (HPV). Recbio has begun technology transfer and drug substance to be used for the manufacture of its Recombinant 9-valent HPV vaccine, REC603, to BE. The transfer includes formulation, filling, packaging, and future drug substance production tech.
In this deal, BE will sell the HPV9 vaccine in India alone and will also participate in UNICEF and PAHO tenders in the rest of the world's markets. It guards against nine types of Human Papillomavirus (HPV), which are responsible for causing cancer of the cervix, vulva, vagina, anus, and oropharynx, and also genital warts.
Also Read: Bharat Biotech and GSK Cut Malaria Vaccine Price to Save More Lives in Africa
HPV remains a global public health concern that affects hundreds of thousands of cancer cases every year. The 9-valent vaccine has been performing well in preventing about 90% of cervical cancer and diseases. The REC603 vaccine by Recbio is in Phase III clinical trials in China in subjects aged between 9 to 45 years.
The collaboration will leverage BE's state-of-the-art manufacturing capability to increase vaccine availability and supply in India and globally. Recbio will further offer ongoing clinical development and regulatory assistance to ensure smooth transfer and timely market access.
Leader's Thought: Anti-Infectives: How New Research is Shaping Infection Control
Recbio CEO Dr. Liu Yong was optimistic for foreign market growth with BE. "It is a robust strategic fit with our purpose to improve global health through affordable vaccines that provide a healthier world for everyone," stated Biological E's Managing Director, Mahima Datla.
